+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Hemorrhoids - Pipeline Insight, 2021

  • ID: 4989318
  • Drug Pipelines
  • March 2021
  • Region: Global
  • 60 pages
  • DelveInsight

FEATURED COMPANIES

  • Panacea Biotec Ltd
  • Peritech Pharma Ltd.
  • Ventrus Biosciences, Inc
This “Hemorrhoids- Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Hemorrhoids pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Hemorrhoids Understanding

Hemorrhoids: Overview

Hemorrhoids, also called piles, are swollen and inflamed veins around the anus or in lower rectum. External hemorrhoids form under the skin around the anus. Internal hemorrhoids form in the lining of the anus and lower rectum. Symptoms of hemorrhoids depend on the type of hemorrhoid. External hemorrhoid symptoms include anal itching. Internal hemorrhoid symptoms include rectal bleeding. Certain toilet habits, constipation, a low-fiber diet, and aging may cause hemorrhoids.

"Hemorrhoids - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hemorrhoids pipeline landscape is provided which includes the disease overview and Hemorrhoids treatment guidelines. The assessment part of the report embraces, in depth Hemorrhoids commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hemorrhoids collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Hemorrhoids R&D. The therapies under development are focused on novel approaches to treat/improve Hemorrhoids.

Hemorrhoids Emerging Drugs Chapters

This segment of the Hemorrhoids report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hemorrhoids Emerging Drugs

CITI-002: Citius Pharmaceuticals

CITI-002 is a topical formulation of halobetasol and lidocaine that is intended to provide anti-inflammatory and anesthetic relief to individuals suffering from hemorrhoids. Citius’ halobetasol and lidocaine formulation could become the first FDA-approved product to treat hemorrhoids in the United States.

Hemorrhoids: Therapeutic Assessment

This segment of the report provides insights about the different Hemorrhoids drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Hemorrhoids

There are approx. 10+ key companies which are developing the therapies for Hemorrhoids. The companies which have their Hemorrhoids drug candidates in the most advanced stage, i.e. Phase II include, Citius Pharmaceuticals.

Phases

This report covers around 10+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Hemorrhoids pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hemorrhoids: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Hemorrhoids therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hemorrhoids drugs.

Hemorrhoids Report Insights
  • Hemorrhoids Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Hemorrhoids Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions Answered

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Hemorrhoids drugs?
  • How many Hemorrhoids drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hemorrhoids?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Hemorrhoids therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Hemorrhoids and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Pacira Pharmaceuticals, Inc
  • Peritech Pharma Ltd.
  • Ventrus Biosciences, Inc
  • Nivagen Pharmaceuticals Inc.
  • Citius Pharmaceuticals, Inc.
  • Panacea Biotec Ltd
Key Products
  • SKY0402
  • PP110 Gel
  • Iferanserin
  • Hydrocortisone Acetate Suppository, 25 mg
  • Hydrocortisone acetate and lidocaine hydrochloride
  • Euphorbia tablets


This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Panacea Biotec Ltd
  • Peritech Pharma Ltd.
  • Ventrus Biosciences, Inc
Introduction

Executive Summary

Hemorrhoids: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Hemorrhoids - Analytical Perspective

In-depth Commercial Assessment
  • Hemorrhoids companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Hemorrhoids Collaboration Deals
  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
  • Comparative Analysis
Drug Name: Company Name
  • Product Description
  • Research and Development
  • Product Development Activities
Mid Stage Products (Phase II)
  • Comparative Analysis
CITI-001: Citius Pharmaceuticals
  • Product Description
  • Research and Development
  • Product Development Activities
Early Stage Products (Phase I)
  • Comparative Analysis
Drug Name: Company Name
  • Product Description
  • Research and Development
  • Product Development Activities
Preclinical and Discovery Stage Products
  • Comparative Analysis
Drug Name: Company Name
  • Product Description
  • Research and Development
  • Product Development Activities
Inactive Products
  • Comparative Analysis
Hemorrhoids Key Companies

Hemorrhoids Key Products

Hemorrhoids- Unmet Needs

Hemorrhoids- Market Drivers and Barriers

Hemorrhoids- Future Perspectives and Conclusion

Hemorrhoids Analyst Views

Hemorrhoids Key Companies

Appendix

List of Tables
Table 1 Total Products for Hemorrhoids
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures
Figure 1 Total Products for Hemorrhoids
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown
  • Pacira Pharmaceuticals, Inc
  • Peritech Pharma Ltd.
  • Ventrus Biosciences, Inc
  • Nivagen Pharmaceuticals Inc.
  • Citius Pharmaceuticals, Inc.
  • Panacea Biotec Ltd
Note: Product cover images may vary from those shown
Adroll
adroll